Literature DB >> 11570143

Immunologic defects and vaccination in patients with chronic renal failure.

E L Pesanti1.   

Abstract

Patients with chronic renal failure suffer from defective host defenses which are directly the result of the renal impairment, in addition to those dependent on the primary illness leading to the renal failure. The mechanisms underlying the defective responses in phagocytic cells, lymphocytes and antigen processing are likely due to either failure to adequately eliminate suppressive compounds by the defective kidneys or to improper metabolic processing of the factors by the damaged renal parynchema. That some of the defects are reversed by transplantation and not dialysis suggests that renal parenchymal metabolic activities may be involved, although it is also possible that functioning glomerular cells are capable of filtering substances that membranes are not currently capable of eliminating. The current strategy for dealing with the immunodeficiency appears to be totally based on developing means to circumvent the defective function. The other approach, correction of the impaired function, cannot be even considered until the mechanisms underlying the defective function of the cells involved in defenses are better delineated. It seems possible that one or a few compounds are pivotal in altering the function of all the affected cell lines, since, with only a small amount of effort, it is possible to relate the dysfunction to abnormal cell membrane functions in phagocytic cells, dendritic cells and lymphocytes. Until the biochemical basis of the dysfunction of all the cell types affected are better defined, such exercises cannot be translated into better management of patients with chronic renal failure. Proper function of host defenses requires that appropriate cells can properly respond to threats to host viability. For the cells of the immune system (phagocytes and lymphocytes) this means that their response to regulatory molecules be appropriate, that their mobility be normal, that their adherence to substrates be preserved, and that they can generate the appropriate response to the challenge. For neutrophils, for example, it is necessary that they recognize and mobilize appropriately to chemotactic stimuli, that they be able to adhere to and migrate through endothelial lining, that their phagocytic activity be sufficient, and that they can kill and degrade endocytosed particles and generate appropriate secretions. Similar lists of requirements for good function can be generated for any cell type in the immune defense system. Uremia, as well as currently available treatments for uremia, directly or indirectly alters the function of all phases of appropriate immune cell function. Defective host responses in uremia have been recognized for decades and there has been considerable effort in the past decade to better define the extent and mechanisms of impaired defenses. Despite the multitude of major defects in humoral, cellular, and inflammatory processes, uremic patients who are cared for today, although they remain at higher risk of serious infectious complications, can and do maintain a good quality of life, with most remaining free of major infections for years and decades.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11570143     DOI: 10.1016/s0891-5520(05)70174-4

Source DB:  PubMed          Journal:  Infect Dis Clin North Am        ISSN: 0891-5520            Impact factor:   5.982


  33 in total

1.  Chronic kidney disease worsens sepsis and sepsis-induced acute kidney injury by releasing High Mobility Group Box Protein-1.

Authors:  Asada Leelahavanichkul; Yuning Huang; Xuzhen Hu; Hua Zhou; Takayuki Tsuji; Richard Chen; Jeffrey B Kopp; Jürgen Schnermann; Peter S T Yuen; Robert A Star
Journal:  Kidney Int       Date:  2011-08-10       Impact factor: 10.612

2.  Sex bias in response to hepatitis B vaccination in end-stage renal disease patients: Meta-analysis.

Authors:  Hossein Khedmat; Aghdas Aghaei; Mohammad Ebrahim Ghamar-Chehreh; Shahram Agah
Journal:  World J Nephrol       Date:  2016-01-06

3.  Beneficial in vitro effect of N-acetyl-cysteine on oxidative stress and apoptosis.

Authors:  Jacek Zachwieja; Marcin Zaniew; Waldemar Bobkowski; Ewa Stefaniak; Alfred Warzywoda; Danuta Ostalska-Nowicka; Agnieszka Dobrowolska-Zachwieja; Maria Lewandowska-Stachowiak; Aldona Siwińska
Journal:  Pediatr Nephrol       Date:  2005-04-05       Impact factor: 3.714

4.  Effect of vitamin D level on the immunogenicity to hepatitis B vaccination in dialysis patients.

Authors:  Rajesh Jhorawat; Shailendra Jain; Ajay Pal; Sandeep Nijhawan; Pankaj Beniwal; Dhananjai Agarwal; Vinay Malhotra
Journal:  Indian J Gastroenterol       Date:  2016-02-15

5.  The risk of infection-related hospitalization with decreased kidney function.

Authors:  Lorien S Dalrymple; Ronit Katz; Bryan Kestenbaum; Ian H de Boer; Linda Fried; Mark J Sarnak; Michael G Shlipak
Journal:  Am J Kidney Dis       Date:  2011-09-09       Impact factor: 8.860

Review 6.  Epidemiology of acute infections among patients with chronic kidney disease.

Authors:  Lorien S Dalrymple; Alan S Go
Journal:  Clin J Am Soc Nephrol       Date:  2008-07-23       Impact factor: 8.237

7.  The duration of hepatitis B vaccine immunity in pediatric dialysis patients.

Authors:  Rita D Sheth; Melissa F Peskin; Xianglin L Du
Journal:  Pediatr Nephrol       Date:  2014-05-17       Impact factor: 3.714

8.  Improving hepatitis B vaccine efficacy in end-stage renal diseases patients and role of adjuvants.

Authors:  Mohammad Hossein Somi; Babak Hajipour
Journal:  ISRN Gastroenterol       Date:  2012-09-18

9.  Controversial report regarding seroprevalence of hepatitis B and C viruses among hemodialysis patients in kerman province, South-East iran.

Authors:  Mojgan Noroozi Karimabad; Gholamhossein Hassanshahi; Mohammad Kazemi Arababadi
Journal:  Hepat Mon       Date:  2013-03-13       Impact factor: 0.660

Review 10.  Immune dysfunction in uremia—an update.

Authors:  Gerald Cohen; Walter H Hörl
Journal:  Toxins (Basel)       Date:  2012-10-24       Impact factor: 4.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.